H.C. Wainwright raised the firm’s price target on BioXcel Therapeutics (BTAI) to $8 from $3 and keeps a Buy rating on the shares. The firm cites After the dilution associated with the most recent equity financing in March as well as the impact of the reverse stock split implemented in February for the new target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BTAI:
- BioXcel receives positive recommendation from DSMB for SERENITY Phase 3 trial
- BioXcel Granted Nasdaq Compliance Extension Until September
- BioXcel granted extension to regain compliance with Nasdaq listing requirement
- BioXcel Therapeutics Advances Clinical Trials Amid Financial Adjustments
- BioXcel Therapeutics reports Q1 EPS ($1.50) vs. ($13.89) last year